Still Flaring? Why Your Colon Won't Heal: New Rinvoq vs Omvoh UC Data

If you're still dealing with urgency, bleeding, abdominal pain, or unpredictable flares despite treatment, you're not alone. Many people with moderate to severe ulcerative colitis (UC) cycle through multiple medications before finding one that truly controls inflammation and allows the colon to heal.

Two newer advanced therapies — Rinvoq (upadacitinib) and Omvoh (mirikizumab) — are changing the conversation. If you're comparing Rinvoq vs Omvoh for ulcerative colitis, here's what current clinical data shows, explained in clear and practical terms.

---

Why Your Colon May Not Be Healing

Ulcerative colitis is not just about symptoms. It's about ongoing immune-driven inflammation in the lining of the colon. Even when symptoms improve, microscopic inflammation can continue — and that increases the risk of:

• Frequent flares
• Steroid dependence
• Hospitalization
• Colon damage over time

Modern treatment goals now focus on:

• Clinical remission (minimal to no symptoms)
• Endoscopic remission (visible healing on colonoscopy)
• Steroid-free remission
• Long-term disease control

If you're still flaring, it may be because:

• Your current medication isn't targeting the right immune pathway
• Your body has stopped responding to a biologic
• You never achieved deep remission in the first place

That's where newer options like Rinvoq and Omvoh come in.

---

Rinvoq vs Omvoh for Ulcerative Colitis: How They Work

Understanding the difference starts with how each drug targets inflammation.

✅ Rinvoq (Upadacitinib)

• Type: Oral JAK1 inhibitor
• How it works: Blocks Janus kinase (JAK) pathways inside immune cells, reducing multiple inflammatory signals at once
• Form: Daily pill
• FDA approved for UC: 2022 (moderate to severe)

Rinvoq works inside immune cells, broadly dampening inflammatory signaling. Because it acts quickly on multiple pathways, symptom improvement can happen relatively fast.

---

✅ Omvoh (Mirikizumab)

• Type: IL-23 inhibitor (monoclonal antibody)
• How it works: Targets the IL-23 cytokine, a key driver of chronic intestinal inflammation
• Form: IV infusions for induction, then maintenance injections
• FDA approved for UC: 2023 (moderate to severe)

Omvoh works more selectively, blocking one specific inflammatory messenger (IL-23). This pathway is strongly linked to long-term immune activation in UC.

---

What the Clinical Trials Show

Rinvoq UC Data (U-ACHIEVE & U-ACCOMPLISH trials)

In large phase 3 trials involving patients who had failed biologics:

• Clinical remission at 8 weeks: Approximately 26–34% (vs ~4–5% placebo)
• Endoscopic improvement: Significant compared to placebo
• Rapid symptom relief: Some patients improved within 2 weeks
• Maintained remission through 52 weeks in maintenance studies

Notably, Rinvoq performed well even in patients who had failed anti-TNF biologics.

---

Omvoh UC Data (LUCENT-1 & LUCENT-2 trials)

In phase 3 trials including biologic-experienced patients:

• Clinical remission at 12 weeks: Around 24% (vs ~13% placebo)
• Maintenance remission at 1 year: Approximately 49% among responders
• Significant improvements in endoscopic healing
• Sustained response over time

Omvoh also showed strong durability, meaning patients who responded were likely to stay well.

---

Rinvoq vs Omvoh for Ulcerative Colitis: Key Differences

Here's a side-by-side breakdown:

🔹 Speed of Symptom Relief

• Rinvoq: Often faster onset (within weeks)
• Omvoh: Improvement typically seen by week 12

If rapid relief is important (for example, severe symptoms), Rinvoq may have an edge.

---

🔹 Route of Administration

• Rinvoq: Oral daily pill
• Omvoh: IV infusions initially, then injections

Some patients prefer pills. Others prefer less frequent injections.

---

🔹 Immune Targeting

• Rinvoq: Broader immune suppression (JAK pathway)
• Omvoh: More selective IL-23 targeting

Broader suppression may mean faster effects — but potentially broader risks.

---

🔹 Safety Profile

This is where differences matter.

Rinvoq carries boxed warnings for:

• Serious infections
• Blood clots
• Cardiovascular events
• Certain cancers

These risks are uncommon but real, especially in:

• Patients over 50
• Smokers
• Those with cardiovascular risk factors

Doctors usually screen carefully before prescribing.

---

Omvoh safety profile:

• Risk of infections
• Elevated liver enzymes in some patients
• Generally no boxed warning like JAK inhibitors

Because Omvoh targets a narrower pathway, its systemic risks may be more limited compared to JAK inhibitors — though long-term real-world data is still accumulating.

---

Which One Is Stronger?

There isn't a simple answer.

In head-to-head trials, these drugs have not been directly compared. However:

• Rinvoq appears to have rapid and robust induction data
• Omvoh shows strong maintenance durability
• Both are effective in biologic-experienced patients

The "stronger" option depends on:

• Your prior medication history
• Your cardiovascular risk
• How quickly you need symptom relief
• Your tolerance for risk
• Personal preference (pill vs infusion/injection)

---

Why Some Patients Still Flare on Advanced Therapy

Even with modern medications, some people:

• Do not respond (primary non-response)
• Lose response over time
• Develop side effects
• Stop treatment too early

Other overlooked causes of persistent symptoms include:

• Inadequate dosing
• Overlapping IBS symptoms
• Infection (like C. difficile)
• Medication non-adherence

If your colon isn't healing, it may not mean you're out of options. It may mean you need:

• Drug level monitoring
• A mechanism switch (e.g., JAK inhibitor vs IL-23 blocker)
• Combination strategy (short-term steroids + advanced therapy)

---

Should You Switch?

You might consider discussing Rinvoq vs Omvoh for ulcerative colitis with your doctor if:

• You're still steroid-dependent
• You've failed anti-TNF therapy
• You've failed integrin inhibitors
• You want faster symptom control
• You've had safety concerns with previous biologics

Switching mechanisms (for example, from anti-TNF to IL-23 or JAK inhibition) is often more effective than switching within the same class.

---

A Quick Self-Check

If you're unsure whether your symptoms suggest uncontrolled UC or something else, Ubie's free AI-powered tool can help you quickly assess your Ulcerative Colitis symptoms and understand what questions to ask your doctor at your next visit.

This does not replace medical care, but it can help you prepare for a more informed discussion.

---

The Bottom Line: Rinvoq vs Omvoh for Ulcerative Colitis

Both medications represent meaningful progress in UC treatment.

Rinvoq may be ideal if:

• You need rapid symptom relief
• You prefer oral medication
• You have failed multiple biologics

Omvoh may be ideal if:

• You prefer targeted immune modulation
• You want strong long-term maintenance data
• You have cardiovascular risk factors that make JAK inhibitors less ideal

Neither drug is "mild." Both are serious immune therapies. But uncontrolled ulcerative colitis is also serious.

The goal is not just fewer bathroom trips. The goal is true mucosal healing, fewer hospitalizations, and long-term protection of your colon.

---

When to Speak to a Doctor Urgently

Seek immediate medical attention if you have:

• Severe abdominal pain
• High fever
• Heavy rectal bleeding
• Signs of blood clots (leg swelling, chest pain, shortness of breath)
• Signs of serious infection

Ulcerative colitis can become life-threatening if complications develop. Do not delay care.

---

Final Thoughts

If you're still flaring, it doesn't mean you've failed treatment. It may mean you haven't yet found the right mechanism for your immune system.

Newer data on Rinvoq vs Omvoh for ulcerative colitis shows both can induce and maintain remission in patients who previously had limited options.

The next best step? Speak to a gastroenterologist about your symptoms, treatment history, and risk profile. Bring questions. Ask about mucosal healing. Ask about long-term safety.

You deserve a colon that heals — not just one that temporarily quiets down.